Free Trial

111 Q4 2023 Earnings Report

111 logo
$5.82 +0.08 (+1.39%)
As of 01/31/2025 03:59 PM Eastern

111 EPS Results

Actual EPS
-$3.40
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

111 Revenue Results

Actual Revenue
$578.69 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

111 Announcement Details

Quarter
Q4 2023
Time
Before Market Opens

Conference Call Resources

111 Earnings Headlines

111, Inc. (NASDAQ:YI) Short Interest Up 167.4% in January
111 Inc ADR trading halted, news pending
Elon’s #1 AI Stock” SET TO SOAR
Forget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.
111, Inc. Announces ADS Ratio Change
See More 111 Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like 111? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 111 and other key companies, straight to your email.

About 111

111 (NASDAQ:YI) engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies. The B2B segment includes the sale of pharmaceutical products to pharmacy customers through 1 Drug Mall. The company was founded by Gang Yu and Jun Ling Liu in May 2013 and is headquartered in Shanghai, China.

View 111 Profile

More Earnings Resources from MarketBeat